-
公开(公告)号:US10047116B2
公开(公告)日:2018-08-14
申请号:US14349142
申请日:2012-10-01
申请人: MX Adjuvac AB
发明人: Bror Morein , Saideh Berenjian , Kafei Hu
IPC分类号: A61K39/00 , C07J9/00 , A61K31/255 , A61K31/337 , A61K31/52 , A61K31/593 , A61K31/704 , A61K31/7068 , A61K39/145 , A61K39/39 , A61K36/73 , C12Q1/48 , G01N33/50 , A61K9/51 , A61K39/12
CPC分类号: C07J9/00 , A61K9/5123 , A61K31/255 , A61K31/337 , A61K31/52 , A61K31/593 , A61K31/704 , A61K31/7068 , A61K36/73 , A61K39/12 , A61K39/145 , A61K39/39 , A61K2039/5252 , A61K2039/55555 , A61K2039/55577 , A61K2300/00 , C12N2760/16134 , C12N2760/16234 , C12Q1/485 , G01N33/5011 , G01N2800/52 , Y10T428/2982
摘要: The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.
-
公开(公告)号:US20180125936A1
公开(公告)日:2018-05-10
申请号:US15564183
申请日:2016-03-23
IPC分类号: A61K38/18 , A61K31/255 , A61K31/4439 , A61K31/555 , A61K33/24 , A61K38/17 , A61K38/22 , A61K39/00 , A61K45/00 , A61P35/00
CPC分类号: A61K38/18 , A61K31/255 , A61K31/4439 , A61K31/555 , A61K33/24 , A61K38/1709 , A61K38/177 , A61K38/22 , A61K39/00 , A61K39/0011 , A61K45/05 , A61K45/06 , A61K2300/00 , A61P35/00 , C12N2310/127 , C12N2310/16
摘要: The present invention relates generally to a method of treating a neoplastic condition. More particularly, the present invention is directed to a method of selectively sensitising neoplastic cells prior to chemotherapy. The method of the present invention is predicated on administering chemotherapy treatment subsequently to neoplastic cell sensitisation via the exposure of these cells to an activin type 1 B receptor (ACVR1B) antagonist. The present findings have now enabled the development of a new neoplastic treatment regime exhibiting both higher efficacy and reduced side effects for patients and, still further, a means of effectively treating chemoresistant neoplasms.
-
公开(公告)号:US20180009943A1
公开(公告)日:2018-01-11
申请号:US15545272
申请日:2016-01-20
发明人: Donald BROOKS , Jayachandran KIZHAKKEDATHU , Rajesh SHENOI , Marie WEINHART , Benjamin LAI , Rainer HAAG , Dominic GROEGER
IPC分类号: C08G65/334 , A61K31/255 , A61K38/36
CPC分类号: C08G65/3344 , A61K31/255 , A61K38/36 , C08G65/32 , C08G2650/54
摘要: The invention relates to a linear polyglycerol compound, comprising a backbone of linearly linked glycerol residues. This compound is characterized in that it carries a plurality of substituents in the nature of covalently bound sulfates, wherein a degree of substitution of the backbone is preferably between 30 and 100%. A method of manufacturing the compound as well as uses of this compound and similar compounds are also disclosed.
-
公开(公告)号:US20170362593A1
公开(公告)日:2017-12-21
申请号:US15536437
申请日:2015-12-21
发明人: Domenico Maiorano
IPC分类号: C12N15/113 , A61K31/381 , G01N33/574 , A61K31/713 , C12Q1/68
CPC分类号: C12N15/1137 , A61K31/255 , A61K31/381 , A61K31/4745 , A61K31/555 , A61K31/7105 , A61K31/713 , A61K33/24 , C07K16/18 , C07K16/40 , C12N9/93 , C12N15/113 , C12N2310/14 , C12N2320/31 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y203/02 , C12Y603/02 , G01N33/57496 , G01N2333/9108 , G01N2800/52
摘要: The present invention relates to the use of an inhibitor of Rad18 expression or activity, in treating a tumor or in sensitizing a patient affected with a tumor, to a treatment with an antineoplastic agent that is a DNA damaging chemotherapeutic agent so to both reduce the self renewal of cancer stem cells and increase the DNA damage response thus boosting apoptotic cell death.
-
公开(公告)号:US20170333483A1
公开(公告)日:2017-11-23
申请号:US15651416
申请日:2017-07-17
发明人: Leonard I. Zon , Pulin Li
IPC分类号: A61K35/28 , A61K31/19 , C12N5/0789 , A61K31/255 , A61K31/221 , A61K31/21 , A61K31/095 , A61K35/12
CPC分类号: A61K35/28 , A61K31/095 , A61K31/19 , A61K31/21 , A61K31/221 , A61K31/255 , A61K2035/124 , C12N5/0647 , C12N2500/36 , C12N2501/999
摘要: Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.
-
公开(公告)号:US09821008B2
公开(公告)日:2017-11-21
申请号:US15038585
申请日:2014-11-25
IPC分类号: A61K33/24 , A61K31/185 , A61K45/06 , A61K31/255 , C07C309/47 , C07C309/67 , C07C309/73 , C07C317/36 , C07C323/66
CPC分类号: A61K33/24 , A61K31/185 , A61K31/255 , A61K45/06 , C07C309/47 , C07C309/67 , C07C309/73 , C07C317/36 , C07C323/66 , A61K2300/00
摘要: Compositions and methods for inhibiting the DNA repair protein complex, ERCC1-XPF, and methods to enhance clinical responses to anticancer drugs that interact with DNA such as cisplatin, and to overcome drug resistance due to DNA repair mechanisms, are described.
-
7.
公开(公告)号:US09783487B2
公开(公告)日:2017-10-10
申请号:US15227237
申请日:2016-08-03
IPC分类号: C07C229/42 , A61K45/06 , A61K31/519 , A61K31/365 , A61K31/42 , A61K31/196 , C07F9/48 , A61K31/662 , C07C309/69 , A61K31/255 , A61K31/197 , C07C229/22 , C07C271/46 , A61K31/27 , C07C271/14 , C07C239/20 , C07C237/30 , C07C229/60 , A61K31/245 , C07C233/54 , C07D303/32 , A61K31/336 , A61K31/137 , C07C271/22 , C07C291/04 , C07C215/68 , C07C229/34 , C07C237/04 , C07D303/36
CPC分类号: C07C229/42 , A61K31/137 , A61K31/196 , A61K31/197 , A61K31/245 , A61K31/255 , A61K31/27 , A61K31/336 , A61K31/365 , A61K31/42 , A61K31/519 , A61K31/662 , A61K45/06 , C07B2200/07 , C07C215/68 , C07C229/22 , C07C229/34 , C07C229/60 , C07C233/54 , C07C237/04 , C07C237/30 , C07C239/20 , C07C271/14 , C07C271/22 , C07C271/46 , C07C291/04 , C07C309/69 , C07D303/32 , C07D303/36 , C07F9/4808
摘要: β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
-
公开(公告)号:US20170246137A1
公开(公告)日:2017-08-31
申请号:US15461572
申请日:2017-03-17
IPC分类号: A61K31/255 , A61K9/08 , A61K9/00
CPC分类号: A61K31/255 , A61K9/0019 , A61K9/0053 , A61K9/08 , A61K9/2018 , A61K9/2054 , A61K9/4858 , A61K9/4866 , A61K31/10
摘要: The invention relates to the use of Sulfestrol (diethylstilbestrol sulfate) in a method of curative or palliative treatment of cancer in a mammal. The inventors have unexpectedly found that Sulfestrol can suitably be employed as an effective drug in the treatment of cancer in mammals. The inventors have further discovered that Sulfestrol can be administered even in high dosages without giving rise to serious side effects. Besides the clinical use of Sulfestrol the present invention also relates to oral dosage units comprising Sulfestrol and to sterile liquids for intravenous administration that comprise Sulfestrol.
-
公开(公告)号:US09737567B2
公开(公告)日:2017-08-22
申请号:US14691870
申请日:2015-04-21
发明人: Leonard I. Zon , Pulin Li
IPC分类号: A01N63/00 , A61K35/28 , A61K31/19 , A61K31/221 , A61K31/255 , C12N5/0789 , A61K31/095 , A61K31/21 , A61K35/12
CPC分类号: A61K35/28 , A61K31/095 , A61K31/19 , A61K31/21 , A61K31/221 , A61K31/255 , A61K2035/124 , C12N5/0647 , C12N2500/36 , C12N2501/999
摘要: Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.
-
10.
公开(公告)号:US09724345B2
公开(公告)日:2017-08-08
申请号:US15154919
申请日:2016-05-13
IPC分类号: A61K31/496 , A61K9/00 , A61K9/107 , A61K47/10 , A61K31/255 , A61K9/08 , A61K47/02 , A61K47/26
CPC分类号: A61K31/496 , A61K9/0019 , A61K9/08 , A61K9/1075 , A61K31/255 , A61K47/02 , A61K47/10 , A61K47/26
摘要: There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases.
-
-
-
-
-
-
-
-
-